Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.
NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial NCT06904872 remains recruiting per live web sources, with estimated primary completion Feb 2026. No public readout, topline results, or outcome data found across searches for sponsor announcements, press releases, or news. No evidence of positive/negative framing.
Found Apr 6, 2026, 2:58 PMReviewed Apr 6, 2026, 3:00 PM
NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial NCT06904872 is recruiting with primary completion estimated for 2026-02-01. No results posted on ClinicalTrials.gov. Available positive readouts (PS volume reduction) are from separate open-label IITs (pediatric or mixed, non-randomized, different sites) and explicitly not this Phase 2 placebo-controlled adult study without CIC. Evidence is not trial-specific.
Found Apr 6, 2026, 2:08 PMReviewed Apr 6, 2026, 2:19 PM
NO_DECISIONDismissed90% confidencemanual-chat-review
Will the results be positive?
ClinicalTrials.gov still lists this study as recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.
Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:32 PM
NO_DECISIONDismissed97% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific Phase 2 readout is publicly available yet. The study record still shows recruiting with estimated primary completion on 2026-02-28, and sponsor communications say enrollment/screening are ongoing and placebo-controlled study data are expected in 2026. That is insufficient to call the outcome positive or negative.
Found Apr 3, 2026, 4:05 PMReviewed Apr 3, 2026, 4:47 PM
Web Searchcdek.pharmacy.purdue.eduJul 12, 2025, 12:00 AM
Trial | NCT06904872
Mirror of the registry record shows NCT06904872 is RECRUITING, with estimated primary completion Feb 28, 2026 and study completion Feb 28, 2026.
Sponsorjaguarhealth.gcs-web.comSep 25, 2025, 12:00 AM
FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease
Sponsor says additional proof-of-concept results may come later in 2025, while data from both placebo-controlled clinical studies are expected in 2026.
Sponsorjaguarhealth.gcs-web.comOct 31, 2025, 12:00 AM
Jaguar Health, Inc.
Company materials list the adult SBS-IF Phase 2 trial status as enrollment at approximately 25% and patient screening continuing.
NO_DECISIONDismissed98% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No public efficacy readout was found for this exact Phase 2 trial. The cited trial records show NCT06904872 was still recruiting/ongoing in 2025-2026, and sponsor communications discussed separate IIT proof-of-concept data rather than results from this placebo-controlled Phase 2 study.
Found Apr 1, 2026, 6:52 PMReviewed Apr 1, 2026, 7:03 PM